XML 25 R30.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) (USD $)	Dec. 31, 2012	Dec. 31, 2011
Summary of deferred tax assets
Net operating loss carry forwards	$ 27,872,000	$ 26,001,000
Orphan drug and research and development credit carry forwards	3,068,000	2,818,000
Other	1,443,000	1,615,000
Total	32,383,000	30,434,000
Valuation allowance	(32,383,000)	(30,434,000)
Net deferred tax assets

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.

+ References+ Details

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to other deductible loss carryforwards not separately disclosed.

+ References+ Details

- Definition

The tax effect as of the balance sheet date of the amount of future tax deductions arising from all unused tax credit carryforwards which have been reduced by a valuation allowance.

+ References+ Details

- Definition

Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.

+ References+ Details